Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - Akebia Therapeutics, Inc. | akba-ex101_385.htm |
| EX-99.1 - EX-99.1 - Akebia Therapeutics, Inc. | akba-ex991_859.htm |
| EX-32.1 - EX-32.1 - Akebia Therapeutics, Inc. | akba-ex321_6.htm |
| EX-31.2 - EX-31.2 - Akebia Therapeutics, Inc. | akba-ex312_8.htm |
| EX-31.1 - EX-31.1 - Akebia Therapeutics, Inc. | akba-ex311_10.htm |
| EX-21.1 - EX-21.1 - Akebia Therapeutics, Inc. | akba-ex211_9.htm |
| EX-10.28 - EX-10.28 - Akebia Therapeutics, Inc. | akba-ex1028_386.htm |
| EX-10.18 - EX-10.18 - Akebia Therapeutics, Inc. | akba-ex1018_316.htm |
| EX-10.13 - EX-10.13 - Akebia Therapeutics, Inc. | akba-ex1013_315.htm |
| EX-10.6 - EX-10.6 - Akebia Therapeutics, Inc. | akba-ex106_314.htm |
| EX-4.5 - EX-4.5 - Akebia Therapeutics, Inc. | akba-ex45_1095.htm |
| 10-K - 10-K - Akebia Therapeutics, Inc. | akba-10k_20171231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-3 No. 333-211175) of Akebia Therapeutics, Inc., |
|
|
(2) |
Registration Statement (Form S-3 No. 333-203206) of Akebia Therapeutics, Inc., |
|
|
(3) |
Registration Statement (Form S-8 No. 333-196748) pertaining to the Amended and Restated 2008 Equity Incentive Plan, the 2014 Incentive Plan, and the 2014 Employee Stock Purchase Plan of Akebia Therapeutics, Inc., |
|
|
(4) |
Registration Statement (Form S-8 No. 333-209469) pertaining to the 2014 Incentive Plan and the 2014 Employee Stock Purchase Plan of Akebia Therapeutics, Inc., |
|
|
(5) |
Registration Statement (Form S-8 No. 333-216475) pertaining to the 2014 Incentive Plan and the 2016 Inducement Award Program of Akebia Therapeutics, Inc., and |
|
|
(6) |
Registration Statement (Form S-8 No. 333-222728) pertaining to the 2014 Incentive Plan and the 2016 Inducement Award Program of Akebia Therapeutics, Inc., |
of our report dated March 12, 2018, with respect to the consolidated financial statements of Akebia Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 12, 2018